Bayer Buys More Crispr Stock After Celgene Sells – Barron’s
Barron’s |
Bayer Buys More Crispr Stock After Celgene Sells
Barron’s A Bayer unit invested $12 million more in the Swiss firm right before a rally that saw the stock rocket. By. Ed Lin. Jan. 31, 2018 1:29 p.m. ET. By. Ed Lin. Jan. 31, 2018 1:29 p.m. ET. Crispr Therapeutics' largest shareholder just invested another $12 … Here's Why Editas Medicine Rose as Much as 15.7% Yesterday Reviewing Crispr Therapeutics (NASDAQ:CRSP) and Iqvia (IQV) Should You Invest in CRISPR Therapeutics AG (CRSP)? A Look at the Insider Trends |
